IRON
HealthcareDisc Medicine, Inc.
$78.63
$-0.46 (-0.58%)
Jan 5, 2026
Price History (1Y)
Analysis
Disc Medicine, Inc., listed on the market under the ticker IRON, operates within the healthcare sector and biotechnology industry. With a substantial market capitalization of $2.97 billion, the company is of significant scale, employing 142 individuals. The financial health of Disc Medicine, Inc. reveals a picture of net loss, with a net income (TTM) of -$181,110,000 and an EBITDA of -$203,400,992. This translates to operating margins, gross margin, and profit margins all being at 0.0%. The company's returns on equity and assets are also negative, standing at -34.8% and -22.6%, respectively. In terms of its balance sheet, Disc Medicine, Inc. maintains a relatively low level of debt at $30.98 million, contrasted with its significant cash reserves of $615.92 million. The valuation context of IRON indicates a negative forward P/E ratio of -11.61 and an EV/EBITDA of -11.80. The price to book ratio is 4.80, while the company's beta stands at 2.58.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Disc Medicine, Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $2.97B
- P/E Ratio
- N/A
- 52-Week High
- $99.50
- 52-Week Low
- $30.82
- Avg Volume
- 602.26K
- Beta
- 2.58
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 142